Welcome! Login | Register
 

Fattman Slams Abraham Over Mismanagement—Stephanie Fattman, appearing Tuesday on The Jordan Levy…

See the Great Pumpkin Fest at the Ecotarium with Your Woo Card—The weekend is fast approaching, and GoLocalWorcester brings…

10 Best Loved Bacon Dishes in Worcester—We all love bacon.

Pagano Media Wins International Davey Award—Pagano Media wins 2014 International Davey Award

Paul Giorgio: Ebola Should Not Be A Political Football—It’s probably a good thing to worry about…

Former Federal Official to Give Lecture at Clark—Dan Sichel, a former senior official at the…

Report: Patriots Bolster Roster With Two Moves—Tuesday's are generally off days at Gillette Stadium.…

Christie Administration Withholds Findings Into Baker Pay-to-Play Investigation—Republican Governors Association Chair Chris Christie and his…

5 Good Things That Happened To The Patriots This Weekend—Pats relaxed as good things happened for them.

Angiulo: A Call to End Mandatory Minimum Sentences in Massachusetts Drug Cases—The Chief Justice of the Massachusetts Supreme Judicial…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.